Invitrogen, Lentigen to Provide Lentivirus Products and Services for Gene Over-Expression
News Aug 05, 2008
Invitrogen Corporation and Lentigen Corporation have announced a partnership to develop and supply gene over-expression products and services. Invitrogen will exclusively commercialize the products and services from the partnership.
Lentiviral vectors are widely accepted in the research community as an effective tool for gene delivery into all mammalian cell types, including neural, blood, and stem cells.
Under the agreement, Invitrogen will provide access to its extensive human and mouse gene libraries for use by Lentigen for the development of ready-to-use lentiviral particles that deliver enhanced functionality and reliability.
Access to these lentiviral products and services will substantially reduce the time that many researchers currently spend to prepare and characterize lentivirus particles in their own laboratories.
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE